Cite
Jiguet-Jiglaire C, Boissonneau S, Denicolai E, et al. Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study. Acta Neuropathol Commun. 2022;10(1):1doi: 10.1186/s40478-021-01305-4.
Jiguet-Jiglaire, C., Boissonneau, S., Denicolai, E., Hein, V., Lasseur, R., Garcia, J., Romain, S., Appay, R., Graillon, T., Mason, W., Carpentier, A. F., Brandes, A. A., Ouafik, L. '., Wick, W., Baaziz, A., Gigan, J. P., Argüello, R. J., Figarella-Branger, D., Chinot, O., & Tabouret, E. (2022). Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study. Acta neuropathologica communications, 10(1), 1. https://doi.org/10.1186/s40478-021-01305-4
Jiguet-Jiglaire, Carine, et al. "Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study." Acta neuropathologica communications vol. 10,1 (2022): 1. doi: https://doi.org/10.1186/s40478-021-01305-4
Jiguet-Jiglaire C, Boissonneau S, Denicolai E, Hein V, Lasseur R, Garcia J, Romain S, Appay R, Graillon T, Mason W, Carpentier AF, Brandes AA, Ouafik L', Wick W, Baaziz A, Gigan JP, Argüello RJ, Figarella-Branger D, Chinot O, Tabouret E. Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study. Acta Neuropathol Commun. 2022 Jan 03;10(1):1. doi: 10.1186/s40478-021-01305-4. PMID: 34980260; PMCID: PMC8722051.
Copy
Download .nbib